Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01644253 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Safety and Efficacy Study of TRU-016
A Phase 1 study, sponsored by Aptevo Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT01644253 is a Phase 1 study that was terminated before completion, run by Aptevo Therapeutics. The registered enrollment target is 87 participants.
The verdict
NCT01644253, a Phase 1 study, was terminated before completion, sponsored by Aptevo Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in patients with CLL; and in combination with bendamustine in patients with PTCL.
Interventions
- BIOLOGICAL 20 mg/kg TRU-016 + Rituximab
- BIOLOGICAL 10 mg/kg TRU-016 + Rituximab
- BIOLOGICAL TRU-016 20 mg/kg + Obinutuzumab
- BIOLOGICAL TRU-016 6-20 mg/kg + idelalisib + rituximab
- BIOLOGICAL TRU-016 10-20 mg/kg + ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2012-09 |
| Est. Completion | 2021-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01644253
The ClinicalTrials.gov registry entry for NCT01644253 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptevo Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 20 mg/kg TRU-016 + Rituximab is the first listed.
NCT01644253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01644253 about?
NCT01644253 is a clinical study titled "Phase 1b Safety and Efficacy Study of TRU-016". The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in patients with CLL; and in combination with bendamustine in patients with PTCL...
What is the current status of trial NCT01644253?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2012-09. Estimated completion is 2021-04-21.
What interventions are being tested in trial NCT01644253?
The interventions under investigation include: 20 mg/kg TRU-016 + Rituximab (BIOLOGICAL), 10 mg/kg TRU-016 + Rituximab (BIOLOGICAL), TRU-016 20 mg/kg + Obinutuzumab (BIOLOGICAL), TRU-016 6-20 mg/kg + idelalisib + rituximab (BIOLOGICAL), TRU-016 10-20 mg/kg + ibrutinib (BIOLOGICAL).
Who is sponsoring clinical trial NCT01644253?
This trial is sponsored by Aptevo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.